bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

The Company intends to share with investors the amount of cash,
cash equivalents and marketable securities it had on hand as of
December 31, 2016. Although the Company has not finalized its
financial results for the twelve months ended December 31, 2016,
the Company currently anticipates that its cash, cash equivalents
and marketable securities were approximately $885 million as of
December 31, 2016. This information is unaudited and does not
present all information necessary for an understanding of the
Companys financial condition as of December 31, 2016 and its
results of operations for the twelve months ended December 31,
2016. The Company expects to announce its full results for the
twelve months ended December 31, 2016 on or before March 1, 2017.

Item 7.01 Regulation FD Disclosure.

The Company will be conducting meetings with investors attending
the 35^th Annual J.P. Morgan Healthcare Conference in
San Francisco beginning on January 9, 2017. As part of these
meetings, the Company will deliver the slide presentation
furnished to this report as Exhibit 99.1 and which is
incorporated herein by reference.

See Item 2.02 above, which is incorporated by reference herein.

The information in this report furnished to Items 2.02 and 7.01
shall not be deemed filed for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section. It may
only be incorporated by reference in another filing under the
Exchange Act or the Securities Act of 1933, as amended, if such
subsequent filing specifically references the information
furnished to Items 2.02 and 7.01 of this report.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

About bluebird bio, Inc. (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

bluebird bio, Inc. (NASDAQ:BLUE) Recent Trading Information

bluebird bio, Inc. (NASDAQ:BLUE) closed its last trading session down -0.15 at 68.05 with 657,646 shares trading hands.